Galway, Ireland, Sept. 1, 2009 – AOTI Ltd. announced today that it has been awarded a new contract by the General Services Administration (GSA). AOTI’s Federal Supply Schedule (FSS) contract number is V797P-4209b and the initial contract period is for 5 years.
“We are delighted that the GSA has added our unique Topical Wound Oxygen (TWO2) products for treating Chronic and Acute Wounds and Ulcers to the FSS, enabling all affected patients within the entire; Veterans Administration (VA) system, Indian Health service IHS) and other government facilities worldwide, to have access and reimbursement for our complete product range. Our TWO2 therapy addresses the fundamental reasons these wounds do not heal, by reducing pathogenic bio-burdens and reversing the localized tissue hypoxia, thereby stimulating the underlying cellular mechanisms needed for good tissue to regenerate, stated Mike Griffiths, CEO and President of AOTI Ltd.
Griffiths added “As the world population continues to age, demand for advanced and clinically proven wound care products such as our TWO2 system will increase dramatically. This is no less evident than in the patient populations serviced by the VA and IHS networks. With the availability of our product line to his significant patient segment, AOTI is now even better positioned to become a major player of this growing multi-billion dollar market segment.”
AOTI is founded on a decade of experience in providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in fully closing Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Galway, Ireland with offices throughout the globe. For more information, see www.aotinc.net.